Adoptive cell therapy using regulatory T cells as individualized medicine to promote clinical transplantation tolerance.
Despite the success of organ transplantation, most transplant patients are susceptible to variety of infections and cancer due to the use of potent immunosuppressive drugs for life to prevent transplant rejection. Regulatory T cells are capable of preventing transplant rejection while leaving the immune system's function against infection intact. Thus, adoptive cell therapy using patient-specific regulatory T cells as individualized medicine could promote clinical transplantation tolerance without the use of nonspecific immunosuppressive agents.
Jiang
Shuiping
S
Department of Nephrology and Transplantation, King's College London, Guy's Hospital, London SE1 9RT, United Kingdom. shuiping.jiang@kcl.ac.uk
D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D057285:Precision Medicine / Q000379:methods*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D023001:Transplantation Tolerance / Q000276:immunology*